Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.
AffiliationDepartment of Surgery, South Manchester University Hospitals Trust, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK.
MetadataShow full item record
AbstractVenous thromboembolism (VTE) following breast cancer chemotherapy is common. Chemotherapy-induced alterations in markers of haemostasis occur during chemotherapy. It is unclear how rapidly this occurs, whether this is upregulated in patients developing VTE and whether changes predict for VTE. Markers of haemostasis, functional clotting assays and vascular endothelial growth factor were measured before chemotherapy and at 24 h, 4 days, 8 days and 3 months following commencement of chemotherapy in early and advanced breast cancer patients and in age- and sex-matched controls. Duplex ultrasound imaging was performed after 1 month or if symptomatic. Of 123 patients, 9.8% developed VTE within 3 months. Activated partial thromboplastin time (APTT), prothrombin time (PT), D-dimer, fibrinogen, platelet count, VEGF and fibrinogen were increased in cancer. Fibrinogen, D-dimer, VEGF and tissue factor were increased, at baseline, in patients subsequently developing VTE. D-dimer of less than 500 ng ml(-1) has a negative predictive value of 97%. Activated partial thromboplastin time, PT and thrombin-antithrombin showed significantly different trends, as early as within 24 h, in response to chemotherapy in patients subsequently developing VTE. Markers of coagulation and procoagulants are increased, before chemotherapy, in patients who subsequently develop VTE. A group of patients at minimal risk of VTE can be identified, allowing targeted thrombopropylaxis to the higher risk group.
CitationEarly changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. 2008, 99 (7):1000-6 Br. J. Cancer
JournalBritish Journal of Cancer
- Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis.
- Authors: Kirwan CC, McCollum CN, McDowell G, Byrne GJ
- Issue date: 2015 Jul
- Platelet release of Vascular Endothelial Growth Factor (VEGF) in patients undergoing chemotherapy for breast cancer.
- Authors: Kirwan CC, Byrne GJ, Kumar S, McDowell G
- Issue date: 2009 Oct 24
- Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome.
- Authors: Kirwan CC, McDowell G, McCollum CN, Byrne GJ
- Issue date: 2011 Jun
- D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
- Authors: Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I
- Issue date: 2009 Sep 1
- Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients.
- Authors: Ay C, Pabinger I
- Issue date: 2012 Apr